Medco Chief Medical Officer to Host Warfarin Effectiveness Study Webinar for Investment Community

Wednesday, March 24, 2010 General News J E 4

FRANKLIN LAKES, N.J., March 23 Dr. Robert Epstein, Medco's chief medical officer and president of the Medco Research Institute(TM) will host a webinar to review the Medco-Mayo Warfarin Effectiveness Study (MM-WES) for the investment community on Thursday, March 25, 2010 at 2 p.m. ET.

The presentation may be heard live and the accompanying slides will be available at

Participants can also access the live conference via telephone: Dial in: 1-800-949-5383 from inside the U.S. and Canada, or 1-706-679-3440 from outside the U.S. Please use passcode 64124277.

A replay of the call will be available after the event on March 25, 2010 through April 8, 2010. Dial in: 1-800-642-1687 from inside the U.S., or (706) 645-9291 from outside the U.S. Please use passcode 64124277.

Real Player or Windows Media Player is required to listen to the webcast. Free downloads of both players are available at the webcast site. The webcast will be available for replay for one month following the presentation.

About Medco

Medco Health Solutions, Inc. (NYSE: MHS) is pioneering the world's most advanced pharmacy® and its clinical research and innovations are part of Medco making medicine smarter(TM) for approximately 65 million members.

With more than 20,000 employees dedicated to improving patient health and reducing costs for a wide range of public and private sector clients, and 2009 revenues of nearly $60 billion, Medco ranks 45th on the Fortune 500 list and is named among the world's most innovative, most admired and most trustworthy companies. For more information, go to

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.

SOURCE Medco Health Solutions, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Health Insurance Reform Delivers on Promise of Ame...
Keryx Biopharmaceuticals, Inc. To Hold Conference ...